Molecular Stratification of Triple-Negative Breast Cancers
Authors
Discussion
Loading...
Member takes
Implication
Review demonstrates distinct molecular subgroups in triple-negative breast cancer, highlighting targeted therapeutic opportunities including PARP inhibitors and stem cell agents.
Key Points
- Summarize the molecular classification of triple-negative breast cancers via gene expression profiling and outline the therapeutic implications of these distinct subgroups.
- Synthesized findings from DNA microarray and gene expression analyses classifying breast tumors into biologically distinct categories independent of outcome data.
- Assessed clinical and therapeutic strategies for triple-negative subsets, including conventional cytotoxic chemotherapy, PARP inhibitors, and stem cell-directed agents.
- Gene expression analysis delineates multiple distinct subtypes within triple-negative breast cancer, with the claudin-low group representing a prominent biological subset.
- Chemotherapy provides clinical benefit, but identifying subtype-specific targets reveals actionable vulnerabilities for PARP inhibitors and cancer stem cell therapies.
Cite This Study
Charles M. Perou (2010) studied this question.